Sensitization-enhancing Efficacy of Glycididazole Natrium in Patients with Advanced Non-small Cell Lung Cancer

Objective To explore whether the administration of Glycididazole natrium(CMNa) in advanced nonsmall cell lung cancer(NSCLC) patients can enhance the chemo-sensitivity and to evaluate its safety.Methods Patients with NSCLC confirmed by pathologic and/or cellular evidences were randomly divided into to chemo-sensitivity enhancing(CSE) group (25 patients,TP treating and CMNa) or control group(31 patients,TP treating alone).The chemo-therapy efficacy and side-effects were recorded and analyzed.Results Compared with the control group,the patients in the CSE group seems had a higher total effective rate with no significant difference (40.0% in CSE group,35.5% in control group,P0.05).The mean survival time,1 year and 2 years survival rate of the CSE and control group was 19.4 months,19.5 months,and 70.8%,40.1%,and 69.4%,32.7% respectively.The main side-effects were hematologic toxicity,nausea and vomiting,muscular soreness,peripheral neurotoxicity and renal dysfunction.There was no significant difference existing between groups.Conclusion Administration of CMNa may enhance the chemo-sensitivity of NSCLC without obvious side effects.However,large scale clinical trial is required for the further confirmation of short and long term efficacy.